Past that, most of the competition is not in innovation, but rather in marketing.
"The researchers’ estimate is based on the systematic collection of data directly from the industry and doctors during 2004, which shows the U.S. pharmaceutical industry spent 24.4% of the sales dollar on promotion, versus 13.4% for research and development, as a percentage of US domestic sales of US$235.4 billion." -- http://www.sciencedaily.com/releases/2008/01/080105140107.ht...
Finally, the NIH is picking up most of the tab for fundamental research, and as such, it isn't the drug company that is leading innovation. As such, I find the drug development argument hollow.
Are you claiming that the existing statins address all relevant cases?
> which shows the U.S. pharmaceutical industry spent 24.4% of the sales dollar on promotion, versus 13.4% for research and development, as a percentage of US domestic sales of US$235.4 billion
That's a non sequitor.
> Finally, the NIH is picking up most of the tab for fundamental research
"fundamental research" isn't a significant fraction of the cost of drug development, aka "getting a drug into the pharmacy".
You'd have to also replicate the covered population and make sure that there's a "USA" outside paying for drug development and the like.